Biofarm Bucure Cash Flow Conversion Efficiency
Biofarm Bucure cash flow conversion efficiency. Based on the latest financial reports, Biofarm Bucure (BIO) has a cash flow conversion efficiency ratio of 0.054x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (RON28.64 Million ≈ $6.58 Million USD) by net assets (RON534.78 Million ≈ $122.79 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Biofarm Bucure (2019–2024)
Cash flow conversion efficiency of Biofarm Bucure from 2019 to 2024. This chart illustrates how Biofarm Bucure's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Biofarm Bucure share price for real-time trading data and today's change.
Biofarm Bucure Cash Flow Conversion Ratio Explained
Biofarm Bucure cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Biofarm Bucure Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biofarm Bucure ranked by their cash flow conversion efficiency. Also see Biofarm Bucure market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Guangdong Dcenti Auto-Parts Stock Ltd Co
SHG:603335
|
0.088x |
|
WONIK Materials Co.Ltd
KQ:104830
|
0.029x |
|
Bsm Chemical Co Ltd
SHE:300796
|
0.056x |
|
Deva Holding AS
IS:DEVA
|
0.058x |
|
Tera Light Ltd
TA:TRLT
|
0.028x |
|
Shenzhen Longood Intelligent Electric Co Ltd Class A
SHE:300543
|
0.032x |
|
Sto SE & Co. KGaA
F:STO3
|
0.023x |
|
Hunan Investment Group Co Ltd
SHE:000548
|
0.015x |
Annual Cash Flow Conversion Efficiency for Biofarm Bucure (2019–2024)
The table below shows the annual cash flow conversion efficiency of Biofarm Bucure from 2019 to 2024. Review BIO free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-09-30 | RON478.26 Million ≈ $109.82 Million |
RON57.59 Million ≈ $13.22 Million |
0.120x | -34.47% |
| 2023-09-30 | RON434.41 Million ≈ $99.75 Million |
RON79.83 Million ≈ $18.33 Million |
0.184x | +140.68% |
| 2022-09-30 | RON380.06 Million ≈ $87.27 Million |
RON29.02 Million ≈ $6.66 Million |
0.076x | -63.27% |
| 2021-09-30 | RON332.79 Million ≈ $76.41 Million |
RON69.18 Million ≈ $15.89 Million |
0.208x | +53.41% |
| 2020-09-30 | RON291.55 Million ≈ $66.94 Million |
RON39.51 Million ≈ $9.07 Million |
0.136x | -52.22% |
| 2019-09-30 | RON257.23 Million ≈ $59.06 Million |
RON72.96 Million ≈ $16.75 Million |
0.284x | -- |
About Biofarm Bucure
Biofarm S.A. manufactures and sells medicines in Romania. The company offers a portfolio of products covering therapeutic areas, such as antiallergics, cardiovascular and circulatory, analgesics and antipyretics, dermatology, digestive and metabolic, endocrine, genitourinary, multivitamins, ophthalmology, musculoskeletal, respiratory and ENT, and neurology. It provides prescription and non-prescr… Read more